Encapsulation of lipophilic or amphiphilic therapeutic agents in nano-emulsion
AssigneeCommissariat A L'energie Atomique Et Aux Energies Alternatives
InventorsVeronique Mourier-Robert, Jerome Bibette, Mathieu Goutayer, Fabrice Navarro y Garcia, Isabelle Texier-Nogues
Life of this patent
Estimating the term…
Abstract
The present invention relates to a therapeutic agent formulation in the form of a nano-emulsion, comprising a continuous aqueous phase and at least one dispersed oily phase, in which the oily phase comprises further to the therapeutic agent, at least one amphiphilic lipid and at least one solubilizing lipid, and in which the aqueous phase comprises at least one polyalkoxylated cosurfactant. The invention also relates to a preparation method and use of this formulation.
Claims13
Therapeutic agent formulation in the form of a stable nano-emulsion, comprising a continuous aqueous phase and at least one dispersed oily phase, wherein the surface of the dispersed phase has a zeta potential in a range of from more than −20 mV to less than 20 mV,
- wherein the aqueous phase comprises a polyalkoxylated cosurfactant comprising at least one chain composed of ethylene oxide units or ethylene oxide and propylene oxide units,
- wherein the oily phase also comprises (i) a therapeutic agent, and (ii) at least one phospholipid and at least one solubilising lipid consisting of a mixture of saturated fatty acid glycerides comprising:
- 0% to 20% by weight C8 fatty acids
- 0% to 20% by weight C10 fatty acids,
- 10% to 70% by weight C12 fatty acids,
- 5% to 30% by weight C14 fatty acids,
- 5% to 30% by weight C16 fatty acids, and
- 5% to 30% by weight C18 fatty acids,
- and wherein the dispersed oily phase has an average droplet size of from 10 to 200 nm, so that the therapeutic agent formulation exhibits colloidal stability during storage over a period of at least about 170 days at 40° C. and stealthy character upon administration.
Dependencies are inferred from the claim text.